JP2019167346A5 - - Google Patents

Download PDF

Info

Publication number
JP2019167346A5
JP2019167346A5 JP2019087445A JP2019087445A JP2019167346A5 JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5 JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5
Authority
JP
Japan
Prior art keywords
tumor
combination
bacterial cell
pharmaceutical composition
penetrating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019087445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019167346A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019167346A publication Critical patent/JP2019167346A/ja
Publication of JP2019167346A5 publication Critical patent/JP2019167346A5/ja
Pending legal-status Critical Current

Links

JP2019087445A 2013-07-03 2019-05-07 抗癌組成物 Pending JP2019167346A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361842749P 2013-07-03 2013-07-03
US61/842,749 2013-07-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016524319A Division JP6896420B2 (ja) 2013-07-03 2014-07-01 抗癌組成物

Publications (2)

Publication Number Publication Date
JP2019167346A JP2019167346A (ja) 2019-10-03
JP2019167346A5 true JP2019167346A5 (enExample) 2019-12-26

Family

ID=52144163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016524319A Active JP6896420B2 (ja) 2013-07-03 2014-07-01 抗癌組成物
JP2019087445A Pending JP2019167346A (ja) 2013-07-03 2019-05-07 抗癌組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016524319A Active JP6896420B2 (ja) 2013-07-03 2014-07-01 抗癌組成物

Country Status (10)

Country Link
US (2) US11141492B2 (enExample)
EP (1) EP3016716B1 (enExample)
JP (2) JP6896420B2 (enExample)
KR (1) KR20160027971A (enExample)
CN (1) CN105407974A (enExample)
AU (1) AU2014284396A1 (enExample)
BR (1) BR112015033053A2 (enExample)
CA (1) CA2917102A1 (enExample)
IL (1) IL243323A0 (enExample)
WO (1) WO2015002969A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519734D0 (en) 2015-11-09 2015-12-23 Univ Swansea Cancer therapy
JP2019533149A (ja) * 2016-09-23 2019-11-14 ヴェンタナ メディカル システムズ, インク. 腫瘍試料中の細胞外マトリックスバイオマーカーをスコアリングするための方法及びシステム
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
SG11202108459QA (en) 2019-02-27 2021-09-29 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020232389A1 (en) * 2019-05-16 2020-11-19 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
AU2020382614B2 (en) 2019-11-12 2025-12-11 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CN113769063B (zh) * 2021-09-30 2024-01-19 浙江大学 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用
KR102680316B1 (ko) * 2021-11-01 2024-07-01 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN115838720A (zh) * 2022-07-28 2023-03-24 吉林启众生物科技有限公司 一种携带shSTAT3/shPD-L1重组质粒的减毒沙门氏菌载体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2002059300A2 (en) 2000-12-28 2002-08-01 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
WO2005018332A1 (en) * 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
CN1974759B (zh) * 2006-07-26 2010-06-09 吉林大学 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用
WO2008036841A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US20080311081A1 (en) * 2007-06-15 2008-12-18 Johannes Fruehauf Bacteria mediated gene silencing
NZ601248A (en) * 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2012149364A1 (en) * 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2019167346A5 (enExample)
JP2016530233A5 (enExample)
JP5070051B2 (ja) 癌を治療するための細菌組成物
JP6731405B2 (ja) ウイルス粒子を用いた癌免疫療法
CA2889841C (en) Novel mucosal adjuvants and delivery systems
US20220275099A1 (en) Administration of kynurenine depleting enzymes for tumor therapy
JP2019532047A (ja) 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ
Chen et al. Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I
CN106540256A (zh) 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
Xiao et al. An immunometabolic patch facilitates mesenchymal stromal/stem cell therapy for myocardial infarction through a macrophage‐dependent mechanism
Li et al. Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy
Lam et al. Targeting mesenchymal stem cell therapy for severe pneumonia patients
KRzyKawsKi Combined bacterial and viral treatment: a novel anticancer strategy
Tuthill et al. Thymosin alpha 1: past clinical experience and future promise
CN114632149A (zh) 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用
CN107007830B (zh) 一种无毒株弓形体和中药多糖佐剂组合物的用途、疫苗及制备方法
Kawano et al. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin
EP3876948A1 (fr) Utilisation du microrna mir-27a-5p pour traiter l'inflammation intestinale induite par clostridium difficile
CN113117088B (zh) 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用
Pisano et al. Updates on intravesical therapy
EP0644773B1 (fr) Complexe immunomodulateur anti-sida
US20110144031A1 (en) Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same
Fialho et al. Recent patents on bacterial proteins as potential anticancer agents
JP2017518300A (ja) サイトカイン−キトサンバイオコンジュゲート及びその使用方法